4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000042
SVP, GEN COUNSEL & CORP SEC sold 1,667 shares at an average $78.85 ($131,449)
- SVP, GEN COUNSEL & CORP SEC acquired 1,667 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-08-01 | Option exercise 10b5-1 | +1,667 | $21.41 | $35,690 | 32,493 | D: show line 1 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-08-01 | Sale 10b5-1 | −1,482 | $78.80 | $116,781 | 31,011 | D: show line 2 in the form |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-08-01 | Sale 10b5-1 | −185 | $79.29 | $14,668 | 30,826 | D: show line 3 in the form |
| Open-market sales · 1,667 sh · avg $78.85 · $131,449 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-08-01 | Option exercise · Stock Option (right to buy) 10b5-1 | −1,667 | 181,664 | D: show line 4 in the form |
Loading xslF345X05/wk-form4_1722888387.xml…